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Abstract
Purpose External-beam radiotherapy (EBRT) is the predominant method for localized brain radiotherapy (LBRT) after
resection of brain metastases (BM). Intraoperative radiotherapy (IORT) with 50-kV x-rays is an alternative way to focally
irradiate the resection cavity after BM surgery, with the option of shortening the overall treatment time and limiting normal
tissue irradiation.
Methods We retrospectively analyzed the outcomes of all patients who underwent neurosurgical resection of BM and
50-kV x-ray IORT between 2013 and 2020at Augsburg University Medical Center.
Results We identified 40 patients with 44 resected BM treated with 50-kV x-ray IORT. Median diameter of the resected
metastases was 2.8cm (range 1.5–5.9cm). Median applied dose was 20Gy. All patients received standardized follow-up
(FU) including 3-monthly MRI of the brain. Mean FU was 14.4 months, with a median MRI FU for alive patients of
12.2 months. Median overall survival (OS) of all treated patients was 26.4 months (estimated 1-year OS 61.6%). The
observed local control (LC) rate of the resection cavity was 88.6% (estimated 1-year LC 84.3%). Distant brain control
(DC) was 47.5% (estimated 1-year DC 33.5%). Only 25% of all patients needed WBI in the further course of disease. The
observed radionecrosis rate was 2.5%.
Conclusion IORT with 50-kV x-rays is a safe and appealing way to apply LBRT after neurosurgical resection of BM,
with low toxicity and excellent LC. Close MRI FU is paramount to detect distant brain failure (DBF) early.
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Introduction
In recent decades, improved systemic treatment options
have led to prolonged survival of patients suffering from
metastatic cancer of many tumor entities (e.g., malignant
melanoma, colorectal carcinoma, lung cancer), including
patients with BM. In the early 1990s, the median survival of
highly selected patients treated with resection of single BM
and whole-brain radiotherapy (WBI) was 9.2 months [1]. In
recent series of patients undergoing surgery and focal radio-
therapy for BM, median survival even exceeds 24 months
[2, 3]. As the majority of these patients live longer than
1 year after BM treatment, long-term LC and treatment-
related long-term neurotoxicity have gained increasing im-
portance. Several trials have shown the detrimental effect
of WBI on neurocognitive functioning [4–8]. This led to
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a shift of paradigm in radiotherapy treatment after resec-
tion of BM, away fromWBI and towards focal irradiation of
the resection cavity [9, 10]. Most of this LBRT is adminis-
tered via EBRT, either as stereotactic radiosurgery (SRS) or
as hypofractionated stereotactic radiotherapy (HSRT) [11].
IORT with 50-kV x-rays is an alternative method to irradi-
ate the resection cavity focally after neurosurgical resection
of BM [12]. Since 2013, we have treated patients with IORT
after neurosurgical BM resection on an individual case-by-
case treatment decision basis, always after discussion at and
interdisciplinary consensus of the multidisciplinary tumor
board (MTB). An expert panel of the German Society for
Radiation Oncology (DEGRO) considered IORT after re-
section of BM as standard of care in the year 2017 [Expert
panel decision DEGRO, inquiry 123, 17.02.2017]. Since
then, the Augsburg University Medical Center (UKA) has
run a program offering IORT to patients routinely scheduled
for brain metastasectomy as an alternative to postoperative
external-beam LBRT. A mean of 196 patients (SD 16 pa-
tients) were treated annually for BM at UKA in the past
3 years (2018–2020). Most of these patients (mean 88.5%,
SD 1.4%) were treated with EBRT only, either with WBI
or SRS/HSRT. A mean of 24 patients per year (SD 4 pa-
tients) were treated with a neurosurgical metastasectomy
in this time period. Of those patients, approximately 38%
were treated with IORT, all others with postoperative focal
HSRT to the resection cavity.
Materials andmethods
We conducted a retrospective analysis of all patients who
were treated with IORT after neurosurgical resection of BM
between 2013 and 2020at UKA. We identified all patients
from our oncology information systemMOSAIQ (ELEKTA
AB, Stockholm, Sweden) and gained additional information
via the hospital information system ORBIS (DEDALUS
Healthcare Group AG, Bonn, Germany) and the radiology
information and picture archiving and communication sys-
tem DeepUnity (DEDALUS Healthcare Group AG). The
timepoint for the last FU included in this analysis was
February 5, 2021.
Treatment of all cases followed the recommendations of
the UKA multidisciplinary tumor board (MTB). With re-
gard to patient section, a minimal distance of 5mm between
the border of the contrast-enhancing lesion in MRI and the
optic tract/brainstem was mandatory. Patients with a history
of small-cell lung cancer were excluded. Depending on the
decision of the neurosurgeon, some but not all patients with
centrally located metastases or metastases in the posterior
fossa were excluded. After informed consent of the pa-
tient, neurosurgical brain metastasectomy was performed,
and a frozen section to confirm malignancy of the removed
tumor was prepared. Hereafter, the resection cavity was ir-
radiated with 50-kV x-rays via an INTRABEAM system
(ZEISS MEDITEC AG, Oberkochen, Germany) equipped
with spherical applicators. The device and procedure have
been described previously [12, 13]. Spherical applicator
sizes of this IORT system range from 15 to 50mm in di-
ameter in 5-mm increments. The suitable applicator size
was chosen by the neurosurgeon and radio-oncologist ac-
cording to the size of the resection cavity, providing direct
contact of the cavity walls to the surface of the applica-
tor. Radiation dose was prescribed to the surface of the
applicator (tissue depth 0mm), corresponding to the target
volume/dose concept of postoperative SRS cavity treatment
(GTV=CTV= cavity). Due to the dose distribution of the
system, a 2-mm rim around the cavity received between
63% and 84% of the prescribed dose, depending on the size
of the applicator. The applied dose was reduced to 38–53%
at 5mm and 18–32% at 10mm tissue depth. After IORT, the
applicator was removed and surgery was completed. After
Table 1 Patient and disease characteristics
Patients characteristic
Number of patients 40
Male/female 18/22
Patients alive 24
Median age (range) 62.8 years
(39–83 years)
Patients with previous brain RT 4






Median number of BM at treatment (range) 1 (1–6)
Median size of treated lesion (range) 2.8cm (1.5–5.9cm)
Median size of applicator (range) 2.0cm (1.5–4.0cm)
Median dose (range) 20Gy (13.4–20Gy)
Suspected incomplete resection in MRI 14











Renal cell carcinoma 3





treatment, all patients received standardized FU including
3-monthly MRI of the brain, according to UKA FU pol-
icy for LBRT. All statistical analyses were performed with
EZR (Version 3.4.1/The R Foundation for statistical com-
puting, Vienna, Austria) [14] using Kaplan–Meier methods
and log-rank tests.
Results
We identified 40 patients (22 female/18 male) with 44 re-
sected BM who had been treated with 50-kV x-ray IORT.
For patients characteristics see Table 1. Median age of
these patients at time of treatment was 62.8 years (range
29–83 years). Most patients fitted to recursive partitioning
analysis (RPA) [15] class 2 (31 patients; class 1: 6 patients;
class 3: 3 patients). Median diameter of the resected metas-
tases was 2.8cm (range 1.5–5.9cm). Median applied dose
was 20Gy (range 13.4–20Gy). Four patients had a his-
tory of previous EBRT in the area of resection. All other
patients were newly diagnosed with BM prior to resec-
tion. Median number of BM at treatment time was one
(range 1–6). Maximum number of IORT procedures per
patient was two. All other non-resected brain lesions were
treated with stereotactic radiotherapy (SRS) with the ex-
ception of one patient receiving additional WBI. The pre-
dominant histology of the resected metastases was non-
small-cell lung cancer (14 metastases), followed by breast
cancer (8 metastases) and malignant melanoma (7 metas-
tases). Twenty-four of these patients were simultaneously
suffering from additional tumor burden in organs other than
brain. After treatment, all patients received standardized
Fig. 1 Probability of local control after resection of BM and IORT (the
dotted lines represent the 95% confidence intervals)
follow-up (FU) including 3-monthly MRI of the brain ac-
cording to UKA FU policy for LBRT. Mean follow-up was
14.4 months (SD: 18.1 months), with a median MRI follow-
up for alive patients of 12.2 months (range 0–58.1 months).
At the time of this analysis, 16 of these 40 patients had
died. Median overall survival of all treated patients was
26.4 months (range 0.5–73.0 months), with an estimated
overall survival at 1 year of 61.6%. The observed local
control (LC) rate of the resection cavity was 88.6%, with
estimated LC of 84.3% at 1 year (Fig. 1). All recurrences
except one were histologically proven (NSCLC, breast can-
cer, malignant melanoma, ovarian cancer). Observed distant
brain control (DC) was 47.5% with estimated DC of 33.5%
at 1 year, including 4 patients (10%) who developed lep-
tomeningeal disease (LMD). The estimated LMD rate was
16.2% at 2 years. Only 25% of all patients received WBI in
the further course of disease to achieve DC. All other pa-
tients could be salvaged via focal treatment. IORT did not
increase the perioperative toxicity of brain surgery. Thirty-
day mortality of the 44 interventions was 4.5%, not re-
lated to IORT. One patient died from sepsis arising of the
genitourinary tract and one patient suffered a lethal infarc-
tion of the middle cerebral artery 12 days postoperatively.
One postoperative bleeding, one postoperative formation of
a hygroma, and one wound infection in the area of the cran-
iotomy were observed. One IORT procedure in the posterior
fossa had to be terminated prematurely (applied 13.4Gy of
planned 18Gy) due to detection of an air embolism, which
could be treated without consequential damage for the pa-
tient. Mean time from surgery to discharge from hospital
was 7 days (range 2–27 days). The IORT procedure pro-
longed OR time by a mean of 25min (range 15–42min).
Mean operation time including IORT was 166min (range
97 to 308min). Mean radiation time was 14:55min (range
8:13–27:04min). Twenty-four patients in this series needed
systemic treatment due to additional tumor burden in other
organs. Median time to start of systemic treatment after
surgery was 18 days (range 0 to 130 days) for these pa-
tients. Brain necrosis of any grade after IORT was observed
and histologically proven in one single, symptomatic case
of a lesion in a pre-irradiated area only (observed brain
necrosis rate 2.5% /estimated brain necrosis rate of 6.7% at
1 year). None of the non-pre-irradiated patients experienced
radiologic signs of brain necrosis.
Discussion
To our knowledge, this is the largest published mono-insti-
tutional series of patients treated with IORT after resection
of BM. In contrast to previous publications in this field
[12, 13] reporting mainly LC/DC and toxicity data, we re-
port a wider scope of the implementation of IORT in the
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treatment of patients with BM and its impact on multidis-
ciplinary care. In 2013, we started treating patients with
IORT after neurosurgical BM resection on an individual
case-by-case treatment decision basis after interdisciplinary
discussion and decision in the MTB. With increasing evi-
dence for this procedure [12], this treatment is offered rou-
tinely to patients planned for resection of BM after MTB
recommendation at the UKA as an optional treatment, re-
placing postoperative external beam LBRT in close to 40%
of these patients in the last 3 years of the analyzed pe-
riod. From the patients’ perspective, this is an attractive
option, as it is a “one-stop shop” with no further neces-
sity of adjuvant radiotherapy after discharge from hospital.
The observed LC in our series is definitively in the up-
per range of data reported after brain metastasectomy [3,
16–24]. When we started using IORT for LBRT in 2013,
we applied lower doses of 16Gy according to the Cleveland
protocol [12]. After publication of the toxicity data of the
INTRAGO phase1/2 study [25], we increased the dose in
a stepwise manner and, since 2016, all patients have been
irradiated with 20Gy. Other centers nowadays apply even
higher doses [13, 25, 26]. However, with the reported out-
come of our patients, we do not currently see a necessity for
further dose escalation. Additionally, it has to be taken into
account that the relative biological efficacy (RBE) of the
applied low-energy x-rays (LEX) lies between 1.3 and 1.5
[27–29]. This means that 1Gy applied with 50-kV x-rays
is biologically iso-equivalent to 1.3 to 1.5Gy applied with
photons (RBE 1). This makes 20Gy of LEX IORT biolog-
ically iso-equivalent to 26 to 30Gy of 6-MV photon SRS
[30].
Within the IORT procedure, the choice of the optimally
sized applicator and its correct placement in the resection
cavity is of high importance. The applicator must fit into
the cavity, providing direct contact of the cavity walls to
the surface of the applicator. The treated volume around
the resection cavity receiving a therapeutic dose encom-
passes a seam of tissue of only 5 to 10mm at maximum
[31, 32]. Due to the steep dose gradient of LEX, the choice
of an applicator which is smaller than cavity size will re-
sult in underdosage of parts of the cavity. Applicator sizes
bigger than the cavity space may cause harm to brain tis-
sue by mechanical pressure. For the same reasons, optimal
placement of the applicator within the cavity is also a key
issue. This is based on the experience of the neurosurgeon
only and his knowledge of the operative site, because up
to now, there is no option for three-dimensional imaging of
the patient with the applicator in the treatment position.
This series includes 14 patients with suspected incom-
plete resection in post-operative MRI. This raises the ques-
tion of whether these patients were treated with an insuffi-
cient dose intraoperatively. In a similar postoperative EBRT
setting, we would have treated the patient with an increased
Fig. 2 Probability of local control after resection of BM and IORT
stratified for complete or incomplete resection of BM in postoperative
MRI (the dotted lines represent the 95% confidence intervals)
dose [2]. In our analysis, LC of patients with suspected
residual disease did not significantly differ from the LC
of patients with complete resection on postoperative MRI
(87.4% versus 77.1% at 1 year/p= 0.473; Fig. 2). However,
due to the limited sample size, the validity of this observa-
tion might be questioned. However, the applied biological
effective dose (BED) of the IORT might be sufficient to
control residual disease at the cavity walls in direct contact
with the surface of the applicator. Another aspect of this
issue is the observation that resection cavities after IORT
tend to enhance contrast media more pronouncedly in post-
operative MRI compared to cavities after surgery only. This
might have led to an overdiagnosis of suspected residual
disease in postoperative MRI in patients treated with IORT,
blurring the correct stratification. Nonetheless, in the IORT
setting, the neurosurgeon should utterly strive for complete
resection of the BM.
In this series, more than half of the patients (21 out of
40 patients) experienced DBF after neurosurgical resection
of BM and IORT. We assume this is more likely an effect
of patient selection than of the specific treatment technique.
One-year DBF rates in the literature vary between 20 and
70% [2, 19, 21, 22, 33–36]. Due to FU including 3-monthly
MRI of the brain, all DBF of our patients were diagnosed in
an asymptomatic stage. The majority of these cases could
be successfully salvaged by SRS. Only 25% of all patients
needed WBI due to multiple new BM or LMD in the com-
plete further course of disease to achieve DC. The esti-
mated LMD rate of 16.2% at 2 years in this report matches
perfectly with the reported 2-year LMD rates of patients
treated with focal EBRT postoperatively [33, 35, 37, 38].
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Hence, there is no evidence that the IORT procedure affects
the risk of tumor cell spillage to the cerebrospinal fluid by
neurosurgery.
In this series, IORT did not increase the perioperative
morbidity and mortality of neurosurgical metastasectomy
or the time of hospitalization after surgery [39–41]. The
observed radionecrosis (RN) rate in our patients was 2.5%.
We observed RN formation only in one single case of a le-
sion in a pre-irradiated area. None of the non-pre-irradiated
patients experienced radiologic signs of RN. In the current
literature the rates of RN rage from 5 to 25% for patients
treated with HSRT after resection of BM and tend to be
a little higher for patients treated with SRS in the same
setting [3, 18, 34, 42]. This reasonably low RN rate could
possibly be explained by the relatively small volume of
surrounding brain tissue receiving 10Gy (V10), due to the
steep dose gradient of LEX. V10 is an established risk fac-
tor for RN in SRS. In our series the mean applicator size
was 2.0cm (range 1.5–4.0cm), corresponding to a nomi-
nal mean V10 of 6.12cm3 (range 3.08–35.95cm3). Taking
into account RBE, the corresponding mean V10 (RBE) is
12.97cm3 (range 4.6–48.94cm3). In this context, the combi-
nation of observed high LC and low RN rates in this series
appears to be very favorable. This could only be achieved as
a joint interdisciplinary effort of a multiprofessional team.
Conclusion
IORT with 50-kV x-rays is a safe and convenient way to
apply LBRT after neurosurgical resection of BM. It is as-
sociated with low toxicity and excellent LC. The IORT
procedure has only a minor impact on total OR time and
does not prolong the patients’ recovery time in hospital. For
patients with additional tumor burden, IORT LBRT holds
the chance for an early start of adjacent systemic therapy.
Three-monthly FU with MRI is paramount for LBRT con-
cepts to detect the frequent distant brain failure (DBF) early.
In this setting, WBI could be avoided for 75% of the pa-
tients in the further course of disease, using SRS as an
effective salvage therapy for DBF.
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